* Oscar Health Inc OSCR.N OSCR.K is expected to show a
rise in
quarterly revenue when it reports results on February 4 for the
period ending December 31 2024
* The New York City-based company is expected to report a
72.9% increase in revenue to $2.475 billion from $1.43 billion a
year ago, according to the mean estimate from 7 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Oscar Health Inc is for
a loss
of 59 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Oscar
Health Inc
is $19.00, above its last closing price of $17.30.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2024 -0.18 -0.17 -0.22 Missed -28.3
Jun. 30 2024 0.17 0.16 0.20 Beat 23.7
Mar. 31 2024 0.27 0.27 0.62 Beat 127.9
Dec. 31 2023 -0.73 -0.72 -0.66 Beat 8.7
Sep. -0.47 -0.47 -0.29 Beat 38.6
30 2023
Jun. 30 2023 -0.22 -0.23 -0.07 Beat 69.6
Mar. 31 2023 -0.04 -0.05 -0.18 Missed -254.7
Dec. 31 2022 -1.09 -1.16 -1.05 Beat 9.5
This summary was machine generated January 31 at 21:27 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)